NXTSNEXENTIS TECHNOLOGIES INC.
Is Nexentis Technologies struggling financially?
Yes, by its own account. Nexentis Technologies told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed May 2026
30/100
Fragile
- Sector
- Biotech/Pharma
- Market cap
- $2.6M
- Source filing
- 10-Q 14 May 2026
- Balance sheet
- 30 Jun 2026
Cash runway
-
20months
If the burn speeds up
Empty by Mar 2028
-
28months
If it eases off
Empty by Oct 2028
Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.
Out of cashTwo years or more
The runway math
Cash and short-term investments
$7.6M
÷
Cash burned over the last 12 months
$3.8M
What Nexentis Technologies told the SEC
…management currently is of the opinion that its existing cash will be sufficient to fund operations through the first quarter of 2027. As a result, there is substantial doubt regarding the Company’s ability to continue as a going concern. Management plans to continue securing sufficient financing through the sale of additional equity securities or capital inflows from strategic partnerships. Additional funds may not be…
NEXENTIS TECHNOLOGIES INC., Form 10-Q, filed 14 May 2026.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
What else the numbers show
- Cash burn is narrowing It is spending 31% less cash per year than it was, so the runway above is lengthening rather than shortening.
Other Biotech/Pharma companies that filed the doubt
- ADIL Adial Pharmaceuticals $16.3M
- MBIO Mustang Bio $4.4M
- APRE Aprea Therapeutics $8.1M
- XFOR X4 Pharmaceuticals $400.6M
- MNPR Monopar Therapeutics $723.0M
- CBIO Crescent Biopharma $637.0M